

# Curriculum Vitae

**Renea Elizabeth Henderson, D.O.**

**Research Affiliation**

Elligo Health Research, Inc., 2022- Present  
11612 Bee Cave Road, Bldg. 1, Suites 100 & 150, Austin, TX 78738

**Research Affiliation**

Arkansas Center for Sleep Medicine, PLLC  
11219 Financial Centre Parkway, Suite 101  
Little Rock, AR 72211  
(501) 553-9987  
(501) 553-9986 FAX

**Research Affiliation**

Preferred Research Partners, Inc.  
11219 Financial Centre Parkway, Suite 320  
Little Rock, AR 72211  
(501) 553-9987  
(501) 553-9986 FAX

**Signature:** \_\_\_\_\_



**Date:** \_\_\_\_\_

8/24/22

# Renea Ash Henderson D.O.

11219 Financial Center Parkway, Suite 320  
Little Rock, AR 72211

Phone: (501) 553-9987  
Email: renea54321@gmail.com

## EDUCATION

**University of Arkansas Medical Sciences**  
Child and Adolescent Psychiatry Fellow

July 2016-June 2018

Psychiatry Resident

July 2013- June 2016

**University of North Texas Health Science Center**  
Doctor of Osteopathic Medicine

June 2009-May 2013

**Lamar University**  
BS Biology

2008

**Texas Tech University**  
BS Mechanical Engineering

2003

## Certification

**Adult Psychiatry Board 72789, Certified on 9/18/2017**

**Child Psychiatry Board 10656; Certified on 9/24/2018**

## WORK EXPERIENCE

**Preferred Research Partners, Inc.- Little Rock, AR**  
Sub-Investigator

September 2018-current

- Responsibilities include rater assessments, safety oversight, physical exams & back-up for medical oversight of clinical trial participants on research studies in varying clinical indications

**Chenal Family Therapy- Little Rock, AR**  
Outpatient Clinic Physician

September 2017-current

- Responsibilities include psychiatric evaluations and follow up appointments on clients with a range of diagnoses

**Baptist Behavioral Health- Little Rock, AR**  
Locums Physician

January 2018-current

- Handling inpatient admissions and follow up patients, taking call, as well as new consults in the hospital

**Pinnacle Pointe Hospital- Little Rock, AR**  
Moonlighting Physician

August 2017-current

- Responsibilities include psychiatric evaluations on new admissions, rounding on follow up patients, reviewing lab results, and handling other emergent issues on the unit. This hospital serves only child and adolescent patients

**Rivendell Behavioral Health- Benton, AR**  
Moonlighting Physician

Nov 2016-December 2017

- Responsibilities include taking call over the weekend for new admissions, covering two adult units and a child unit, and rounding on the patients over the weekend

**The BridgeWay- North Little Rock, AR**

January 2016–October 2017

Moonlighting Physician

- Responsibilities include psychiatric evaluations on admissions, rounding on follow up patients, reviewing lab results, and handling other emergent issues on the unit. This hospital has several adult units, a geriatric unit, an acute and residential child unit and a detox unit.

**University of Arkansas Medical Sciences- Little Rock, AR**

February 2015–October 2016

Moonlighting Physician

- Responsibilities psychiatric evaluations on admissions, rounding on follow up patients, reviewing lab results, and handling other emergent issues on the unit under the supervision of an attending on the unit

**STRIVE- North Little Rock, AR**

February 2015–October 2016

Moonlighting Physician

- Completed new RSPMI psychiatric evaluations on child and adolescent patients for STRIVE, which is a school-based program

**LICENSURE**

Arkansas

April 2016 - Present

**CERTIFICATIONS**

Basic Life Support

July 2018

Introductory Training for Autism Diagnostic Observation Schedule, Second Edition

February 2017

CPI Nonviolent Crisis Intervention Training

November 2017

Handle with Care Intervention Training

July 2018

**PUBLICATIONS LIST**

Henderson, R., Repasky-Luke, R., Nedelcut, A., Nedelcut, M. & Hanna-Moussa, S., "Spontaneous Coronary Artery Dissection in a Young Female Two Days Postpartum". 20<sup>th</sup> Annual Research Appreciation Day UNTHSC, Fort Worth, TX. April 2012.

Ash, R., Leslie, A. Design and Development of the Texas Tech Fuel-Cell Powered FutureTruck. SAE 2003. World Congress & Exhibition. Detroit, MI. March 2003.

**PROFESSIONAL MEMBERSHIPS**

- American Psychiatric Association Current
- American Academy of Child and Adolescent Psychiatry Current
- American Medical Association Current
- Arkansas Medical Society Current
- General Residency Counsel Psychiatry, representative 2013-2015
- Residency Education Committee, representative 2013-2015
- Texas Medical Association, Student Chapter 2009-2013  
Treasurer 2009-2010

**CLINICAL TRIALS EXPERIENCE**

2018: Tonix Pharmaceuticals, Military-Related PTSD – TNX-CY-P303

2018: Janssen Research & Development, Insomnia – 42847922ISM2005

2018: Shire Pharmaceuticals – Preschooler ADHD PK – SHP465-112

2018: Shire Pharmaceuticals – Adolescent ADHD – SHP465-308

2018: Shire Pharmaceuticals – Adolescent ADHD – SHP465-309

2018: AbbVie – Testosterone Replacement Therapy for Hypogonadism – M16-100

2018: Otsuka Pharmaceuticals – Post Traumatic Stress Disorder – 331-201-00061

2018: Idorsia Pharmaceuticals – Insomnia – ID-078A301

2018: Idorsia Pharmaceuticals – Insomnia – ID-078A303

2018: Janssen Research & Development – Major Depressive Disorder – 67953964MDD2001

2018: Neos Therapeutics – Attention Deficit Disorder in Children 4-6 y/o – NT0202.1009

2018: Neos Therapeutics – Attention Deficit Disorder in Children 4-6 y/o – NT0202.1010

2018: Tonix Pharmaceuticals - Military-Related PTSD – TNX-CY-P306

2018: Ironwood Pharmaceuticals – GERD – C3718-302

2019: Tonix Pharmaceuticals - PTSD – TNX-CY-P302

2019: Apnimed – Obstructive Sleep Apnea – APN-002

2019: Aptinyx – Post-Traumatic Stress Disorder – NYX-783-2004

2019: Axsome Pharmaceuticals – Treatment-Resistant Depression – AXS05-301

2019: Biohaven Pharmaceuticals – Obsessive Compulsive Disorder – BHV4157-202

2019: Otsuka Pharmaceuticals – Post Traumatic Stress Disorder – 331-201-00071

2019: Takeda – Obstructive Sleep Apnea & Excessive Daytime Sleepiness – Phase 1 – TAK-925-2001

2019: LG Chem – Gout with Hyperuricemia – LG-GDCL002

2019: Applied Therapeutics - Diabetic Cardiomyopathy / Stage B Heart Failure at High Risk of Progression to Overt Heart Failure (Stage C Heart Failure) – AT-001-2001

2019: Adare Pharmaceuticals – Eosinophilic Erosive Esophagitis – SP-1011-003

2019: Allergan - Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis – 3152-301-002

2019: Allergan – Constipation in Children 6-17 y/o – LIN-MD-64

2019: Allergan – Pediatric Participants with Functional Constipation (FC) or Irritable Bowel Syndrome with Constipation (IBS-C) – LIN-MD-66

2019: Allergan – Pediatric Participants (Age 2 to 5 Years) with Functional Constipation – LIN-MD-67

2019: Braintree Laboratories - Bowel Prep for Colonoscopy – BLI4900-302

2019: Phathom Pharmaceuticals – Erosive Esophagitis – EE-301

2019: Phathom Pharmaceuticals – H. Pylori – HP-301

2019: Vanda Pharmaceuticals – Diabetic or Idiopathic Gastroparesis – VP-VLY-686-3301

2019: Vibrant Ltd – Chronic Idiopathic Constipation – V270

2019: OrphoMed – Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) – OM-201

2020: Takeda – Idiopathic Hypersomnia – Phase 1 – TAK-925-2002

2020: Neurogastrx – Diabetic or Idiopathic Gastroparesis – NG101-201

2020: Guardant Health – Colorectal Cancer Screening – 02-GI-002 ECLIPSE

2020: Janssen – Treatment-resistant Depression – 54135419TRD4005

2020: Allergan – Major Depressive Disorder - 2006-308-008

2020: GSK – Meningococcal Vaccine – 205416 (GSK V72\_72)

2020: Janssen – Major Depression & Insomnia – 42847922MDD3002

2020: Novavax – COVID-19 Vaccine – 2019nCoV-301

2020: Supernus – ADHD in Preschoolers – 812P401

2021: Otsuka Pharmaceuticals – ADHD in Children – 405-201-00046

2021: Apnimed – Obstructive Sleep Apnea – APC-003

2021: Apnimed – Obstructive Sleep Apnea – APC-003-OLE

2021: Moderna – CMV Vaccine – mRNA-1647-P301

2021: Phathom Pharmaceuticals – Non-erosive Reflux Disease – NERD-201

2021: Acerus Pharmaceuticals – Ambulatory BP monitoring in Hypogonadism – NAT-2020-01

2021: Purdue Pharma LP – ADHD in Preschoolers & Children – ADA4004

2021: BlackThorn – MDD with Anhedonia &/or GAD – K2-MDD-201

2021: Relmada – Major Depressive Disorder – REL-1017-302

2021: Relmada – Major Depressive Disorder – REL-1017-310

2021: AbbVie – Pediatric Migraine - 3110-305-002

2021: AbbVie – Pediatric Migraine – 3110-306-002

2021: Otsuka Pharmaceuticals – ADHD in Children & Adolescents – 405-201-00016

2021: Otsuka Pharmaceuticals – ADHD in Children & Adolescents – 405-201-00017

2021: Otsuka Pharmaceuticals – ADHD in Children & Adolescents – 405-201-00021

2021: Revolo Pharmaceuticals – Eosinophilic Esophagitis – RVLO 121-04

2022: Mind Med – Generalized Anxiety Disorder – MMED008

2022: Merck – Treatment Resistant Depression – MK1942-006

2022: 89 Bio – NASH – BIO89-100-122

2022: Phathom Pharmaceuticals – Non-erosive Reflux Disease – NERD-301